Gelonghui, January 15 | Secoside (688338.SH) announced the 2023 annual results report. During the reporting period, the company achieved operating income of 276,212,831.30 yuan, an increase of 20.72%; achieved net profit attributable to the owner of the parent company of 116,041,667.88 yuan, an increase of 11.46% year on year; realized net profit attributable to the owner of the parent company after deducting non-recurring profit and loss of 114,181,411.99 yuan, an increase of 13.47% year on year; total assets at the end of the reporting period 1,700,755,292.79 yuan, up 5.51% from the beginning of the reporting period; owners' equity attributable to the parent company was 1,599,377,021.69 yuan, an increase of 6.30% over the beginning of the reporting period.
During the reporting period, the increase in demand for diagnosis and treatment in terminal medical institutions and the introduction of new products such as the SF-9200 led to an increase in sales volume of the company's instruments, reagents, and consumables. The company's revenue increased 20.72% year-on-year. Driven by the increase in operating income, the main financial data and indicators have all achieved varying degrees of growth.